โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago โš  LIVE โ€” European Consumer Safety Watch ๐Ÿ’Š Medicines: 18 in last 7 days ๐ŸŽ Food: 180 in last 7 days ๐Ÿงธ Products: 48 in last 7 days ๐ŸŸข Monitoring: EMA ยท RASFF ยท NVWA ยท FAGG ยท FAVV ยท EFSA ยท Safety Gate โฑ Last fetch: 3 hours ago
๐Ÿ›ก๏ธ EUSW
๐Ÿ‡ฌ๐Ÿ‡ง
๐Ÿ’Š

Zirabev

bevacizumab
Colorectal Neoplasms;Breast Neoplasms;Carcinoma, Non-Small-Cell Lung;Carcinoma, Renal Cell;Uterine Cervical Neoplasms
โœ… Authorised Biosimilar
โœ…
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.

What it's used for

Zirabev in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. Zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status. Zirabev, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. Zirabev in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. Zirabev, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

โš ๏ธ Patient safety

No

๐Ÿ“š Past alerts (2)
โš ๏ธ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.